Clinical trial
Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in…
NCT00148317 · Weill Medical College of Cornell University, Other · Completed
Key facts
| NCT number | NCT00148317 |
|---|---|
| Title | Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma |
| Official title | A Sequential Phase II Trial of the Combination of Bortezomib (VELCADE), Dexamethasone (DECADRON) and Pegylated Liposomal Doxorubicin (DOXIL) Followed by High Dose Cyclophosphamide in Multiple Myeloma Patients |
| Lead sponsor | Weill Medical College of Cornell University, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Bortezomib, dexamethasone, liposomal doxorubicin, cyclophoshamide, filgrastim |
| Enrollment | 38 |
| Start date | Jun 1, 2005 |
| Primary completion | Feb 1, 2011 |
| Completion | Nov 1, 2012 |
| First posted | Sep 7, 2005 |
| Last update posted | Jul 18, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: